Patents by Inventor Karim Adnane BENHADJI

Karim Adnane BENHADJI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA
    Publication number: 20220296607
    Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(IS)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.
    Type: Application
    Filed: June 2, 2022
    Publication date: September 22, 2022
    Applicant: Eli Lilly and Company
    Inventors: Karim Adnane BENHADJI, Gerard Joseph OAKLEY, III
  • Targeted treatment of mature T-cell lymphoma
    Patent number: 11376259
    Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: July 5, 2022
    Assignee: Eli Lilly and Company
    Inventors: Karim Adnane Benhadji, Gerard Joseph Oakley, III
  • TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA
    Publication number: 20190231794
    Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.
    Type: Application
    Filed: October 6, 2017
    Publication date: August 1, 2019
    Applicant: Eli Lilly and Company
    Inventors: Karim Adnane BENHADJI, Gerard Joseph OAKLEY, III
  • USE OF 2-{4-[(4-{[1-CYCLOPROPYL-3-TETRAHYDRO-2H-PYRAN-4-yl)-1H-PYRAZOL-4yl]OXY} PYRIDINE-2-yl)AMINO]PYRIDIN-2-yl}PROPAN-2-OL IN THE TREATMENT OF CANCER
    Publication number: 20190216786
    Abstract: The present invention relates to novel methods of using 2-{4-[(4-{[1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy}pyridin-2-yl)amino]pyridin-2-yl}propan-2-ol or a pharmaceutically acceptable salt thereof to treat physiological conditions such as cancer.
    Type: Application
    Filed: September 22, 2017
    Publication date: July 18, 2019
    Inventors: Karim Adnane BENHADJI, Kyla Elizabeth DRISCOLL, Michael Mauritius Fabio LAHN, Jason Scott SAWYER, Anja Jamandre STAUBER
  • DOSAGE REGIMEN FOR TREATMENT OF SOLID TUMORS
    Publication number: 20190209581
    Abstract: A dosing regimen comprising administering 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating a solid tumor cancer at a specified loading dose for a defined period of doses followed by a maintenance dose and optionally administering a corticosteroid during administration of the loading dose is provided.
    Type: Application
    Filed: August 24, 2017
    Publication date: July 11, 2019
    Applicant: Eli Lilly and Company
    Inventors: Karim Adnane BENHADJI, Eunice Soek Mun YUEN